Please ensure Javascript is enabled for purposes of website accessibility

Why Aphria's Stock Crushed It in April

By George Budwell - May 11, 2020 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Aphria's shares surged higher last month on the heels of a strong Q3 report.

What happened

Shares of the Canadian pot company Aphria (APHA) rose by an eye-catching 25.5% during the month of April, according to data from S&P Global Market Intelligence. Aphria's shares spiked last month for two fundamental reasons.

So what

First off, the company's shares were hammered in March by the COVID-19 sell-off. Investors fled pot stocks during the month of March because of concern over global supply chains and the possible negative impact of shelter-in-place orders on demand for legal cannabis in general. These theoretical headwinds haven't come to much so far this year, and cannabis investors apparently decided to go bargain hunting last month. Aphria's stock was clearly one of the beneficiaries of this trend in April.

Top view of a cannabis plant.

Image source: Getty Images.

Secondly, Aphria posted stellar fiscal third-quarter results on April 14. Thanks mainly to its German subsidiary CC Pharma, Aphria handily beat Wall Street's consensus estimates for both its bottom and top lines for the three-month period. What's more, investors even brushed off the fact that Aphria -- like most Canadian cannabis companies -- decided to pull its financial guidance for the remainder of the current fiscal year due to the ongoing pandemic.    

Now what

Is Aphria's stock still worth buying? It all depends on your view of the global cannabis market. On the bright side, Aphria has one of the strongest balance sheets in the industry and a business model capable of producing growth even in this harsh economic climate. Most other pot companies, in contrast, are burning through their cash reserves at an alarming rate. So if you're optimistic about the long-term prospects for the legal cannabis space, Aphria's stock might be a worthwhile buy.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aphria Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.